AOD 9604 vs semaglutide is a question about evidence first.
A useful comparison tells you what was tested. It doesn't need to crown a peptide champion.
No podium required.
For body weight, the evidence differs
AOD-9604's human obesity trial didn't establish significant weight loss beyond placebo, a comparison with no active ingredient. Its human tolerability report describes a different question: how people tolerated treatment. Being tolerable isn't the same as helping people lose weight.
Semaglutide has demonstrated weight-loss results in people. One direct obesity trial compared semaglutide with tirzepatide. Both groups lost weight on average, with more lost in the tirzepatide group.
The participants were adults who had obesity and didn't have type 2 diabetes. Lilly, tirzepatide's maker, funded it. Participants and researchers knew which medicine each person received. Those details stay beside the finding because they help you judge it.
AOD-9604 wasn't in that trial. Our sources contain no direct AOD-9604 versus semaglutide trial, so they can't give us a percentage advantage for that pair. We can describe the different evidence without inventing the missing experiment.
For a weight-management conversation, that's a meaningful difference. One program failed to establish the intended benefit; semaglutide has human weight-loss evidence. Neither statement tells us what fits a particular reader.
Changing the goal changes the question
The approved product EGRIFTA WR (tesamorelin) targets extra abdominal fat linked to HIV-associated lipodystrophy. That means a shift in where fat sits in the body, in adults living with HIV. Weight-loss management is explicitly excluded by the label.
A separate small study in adults with HIV measured visceral and liver fat. Visceral fat surrounds internal organs. Fatty liver isn't an approved use of tesamorelin.
Those fat measurements can't become a body-weight percentage. The tesamorelin page explains why that matters.
Some comparisons stay unanswered
Our sources don't contain controlled human trials that rank AOD-9604 against CJC-1295 or ipamorelin for weight loss. We leave those comparisons open.
A story about how a compound might work can't fill that gap. Separate studies also don't establish that combining compounds will be safe or useful.
Take a question you can actually use
What are you hoping to change, and which evidence speaks to that goal? That's a useful question to bring to a clinician, along with your concerns about risks and follow-up.
Our AOD-9604 page explains the disappointing human result. The tirzepatide page keeps its benefits and cautions together. The reading list gives you the sources behind both.
We like a decision you can explain, including the reasons you might stop. A bigger headline alone is a thin reason.